Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tunica Albuginea who wrote (4108)	12/30/1997 6:27:00 PM
From: Edderd	Read Replies (1) \| Respond to of 23519

TA IMO the largest market isthe unknown one. Contrary to all the BS you might read most of my patients do not have a clear organic cause for their ED. Most of the diabetics I see do not have PVD, retinopathy, or neuropathy when I see them for ED. A good market for Viagra but the real thing is still going to be MUSE for a while.

To: Tunica Albuginea who wrote (4108)	12/30/1997 9:25:00 PM
From: BigKNY3	Read Replies (2) \| Respond to of 23519

TA: You a real tough one to convince! Here's some data from the 1997 AUA meeting for you to ponder. As you know, DrTom Lue is one of the most respected and influential ED specialists in the world. He was one of investigators of a completed Viagra clinical study conducted on 416 patients in 22 sites. It was probably a Phase II dosage study and was presented at the 1997 AUA meeting. Here's a published abstract of the study that I found on the AOL Vivus Board (3/21/97). Note: that 73% of the patients had ED of organic origin. Viagra at 50 mg improved erections 72.9% of the time, Viagra at 100 mg improved erections 77.8% of the time as compared to 27.7% for placebo. Viagra was "well-tolerated".. I am also attaching a second Viagra abstract from a European multicenter trial of 271 patients studied for 1 year. Only 1% of the patients dropped out of the study due to adverse reactions."The most frequently reported ae's were headache, facial flushing, and indigestion. None of the 25 serious ae's were attributed to sildenafil." BigKNY3 ________________________________________ Abstracts were published on Monday 14 April, 1997 by two Sildenafil (Viagra) research groups. Dr. Tom Lue of San Francisco presented efficacy, safety, and toleration data on 416 patients from 22 sites during an 8 week double-blinded study. The study tested 4 strengths of sildenafil vs placebo given 1 hr before anticipated sexual activity. The erectile dysfunction of the men were assessed as 73% organic, 9% psychogenic, and 18% mixed. Efficacy was assessed by a self-administered questionnaire at week 8. Safety and toleration were evaluated by routine lab tests and recording of adverse events. The following results are highly statistically significant with a p value of Cancel Changes Normal Font Fixed FontSend questions and feedback to webmistress@techstocks.com